- ►diabetesjournals.org H Hui, N Khoury, X Zhao, L Balkir, ED'Amico, A … - Diabetes, 2005 - Am Diabetes Assoc Immunosuppressive drugs are routinely used to provide tolerance after whole
pancreas and islet cell transplantations. While they are essential in inhibiting
graft rejection, little is known about their effect on islet function and ... Cited by 32 - Related articles - All 5 versions
- ►shouxi.net JA Emamaullee, RV Rajotte, P Liston, RG … - Diabetes, 2005 - Am Diabetes Assoc The Edmonton Protocol for treatment of type 1 diabetes requires islets from two
or more donors to achieve euglycemia in a single recipient, primarily because
soon after portal infusion, the majority of the transplanted cells undergo ... Cited by 24 - Related articles - BL Direct - All 8 versions
J Emamaullee, P Liston, RG Korneluk, AMJ … - Am J Transplant, 2005 - interscience.wiley.com Recent advances in clinical islet transplantation have allowed patients with
type 1 diabetes to become insulin independent, but the procedure is limited
since islets from two donors per recipient are typically required. This ... Cited by 21 - Related articles - All 5 versions
- ►aspetjournals.org E Oetjen, D Baun, S Beimesche, D Krause, I … - Molecular pharmacology, 2003 - ASPET Cyclosporin A and tacrolimus are clinically important immunosuppressive drugs.
They share a diabetogenic action as one of their most serious adverse effects.
The underlying mechanism is unknown. Previous studies have shown that ... Cited by 34 - Related articles - BL Direct - All 3 versions
DK Fuhrer, M Kobayashi, H Jiang - Diabetes Obesity and Metabolism, 2001 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 20 - Related articles - BL Direct - All 4 versions
- ►shouxi.net A Plesner, P Liston, R Tan, RG Korneluk, CB … - Diabetes, 2005 - Am Diabetes Assoc Allotransplantation of pancreatic islets represents a promising approach to
treat type 1 diabetes. Destruction of β-cells in islet allografts involves
multiple immune mechanisms that lead to activation of caspases and ... Cited by 14 - Related articles - BL Direct - All 6 versions
L Polastri, F Galbiati, F Bertuzzi, P Fiorina, R … - Acta Diabetologica, 2002 - Springer Abstract Despite the considerable interest for islet and pan- creas
transplantation, remarkably little is known about the direct effects of
immunosuppressive drugs on human β-cell function. We measured different ... Cited by 33 - Related articles - BL Direct - All 3 versions
- ►jimmunol.org ST Grey, C Longo, T Shukri, VI Patel, E … - The Journal of Immunology, 2003 - Am Assoc Immnol Transplantation of an excessive number of islets of Langerhans (two to four
pancreata per recipient) into patients with type I diabetes is required to
restore euglycemia. Hypoxia, nutrient deprivation, local inflammation, and ... Cited by 44 - Related articles - BL Direct - All 4 versions
E Bell, X Cao, JA Moibi, SR Greene, R Young, … - Diabetes, 2003 - Am Diabetes Assoc Rapamycin (sirolimus) is a macrolide fungicide with immunosuppressant properties
that is used in human islet transplantation. Little is known about the effects
of rapamycin on MIN-6 cells and islets. Rapamycin had a dose-dependent, ... Cited by 73 - Related articles - BL Direct - All 4 versions
CT Bussiere, JRT Lakey, AMJ Shapiro, GS … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis The Edmonton Protocol for islet trans- plantation has
provided hope for type 1 diabetic patients. However, this protocol requires
lifelong immunosuppres- sion, specifically sirolimus, a cellular ... Cited by 28 - Related articles - BL Direct - All 4 versions
